Cingulate Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Cingulate Inc. (CING) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $28.40 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $28.40M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $25.89M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $10.95M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $6.12M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $28.40M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $25.89M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $10.95M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $6.12M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $8.90M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $9.52M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $12.21M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $10.04M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $380.93K 10-Q · filed 2025-08-19 |
| 2024-03-31 | $1.11M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $52.42K 10-K · filed 2026-03-18 |
| 2023-09-30 | $1.99M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $349.83K 10-Q · filed 2024-08-13 |
| 2023-03-31 | $1.74M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $5.36M 10-K · filed 2025-03-27 |
| 2022-09-30 | $9.80M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $8.20M 10-Q · filed 2023-08-14 |
| 2022-03-31 | $12.61M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $16.49M 10-K · filed 2024-04-01 |
| 2021-09-30 | $1.92M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $1.04M 10-Q · filed 2022-08-11 |
| 2021-03-31 | $808.24K 10-Q · filed 2022-05-12 |
| 2020-12-31 | $1.20M 10-K · filed 2023-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |